SCHEMBL2277892

SCHEMBL2277892

O=C(C=Cc1cccc(Cl)c1)Nc1cc(Oc2ccccc2)ccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
NPC1 O15118 4/20 0.57
RAB9A P51151 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
CYP3A4 P08684 4/20 0.57
CYP1A2 P05177 3/20 0.57
CYP2C19 P33261 3/20 0.57
TRPA1 O75762 3/20 0.53
MMP1 P03956 4/20 0.52
MMP2 P08253 4/20 0.52
MMP9 P14780 4/20 0.52
MAOB P27338 3/20 0.52
EGFR P00533 3/20 0.52
MAOA P21397 1/20 0.52
ALDH1A1 P00352 4/20 0.50
HPGD P15428 4/20 0.50
MAPT P10636 3/20 0.50
POLB P06746 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2277888 1.00 MEN1 (0.57) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2270181 0.90 TRPA1 (0.60) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2270176 0.90 TRPA1 (0.60) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2278170 0.89 TRPA1 (0.68) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2278165 0.89 TRPA1 (0.68) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2276170 0.87 MEN1 (0.61) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2274013 0.87 TRPA1 (0.53) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2274015 0.87 TRPA1 (0.53) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2276168 0.87 MEN1 (0.61) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL8059612 0.86 MEN1 (0.65) MEN1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 MEN1 3105/4885KMT2A 1669/4885NPC1 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.